Get to know our clinical trials
Phase 2 clinical trial to investigate CYP-001 in combination with corticosteroids in adults with high-risk acute graft-versus-host disease
THE AIM OF THIS STUDY IS TO DEMONSTRATE WHETHER CYP-001 ADDED TO REGULAR CORTICOSTEROID THERAPY IS SAFE AND EFFECTIVE IN TREATING HIGH-RISK GVHD.
Status
In recruitment
headquarters
Pamplona
Early phase
Technical Summary
- PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-COMPARATIVE, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CYP-001 IN COMBINATION WITH CORTICOSTEROIDS COMPARED TO CORTICOSTEROIDS IN MONOTHERAPY FOR THE TREATMENT OF ACUTE HIGH-RISK GRAFT-VERSUS-HOST DISEASE
- Code EudraCT: 2022-502673-41-00
- Protocol number: CYP-GVHD-P2-01
- Promoter: Cynata Therapeutics Limited
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.